Cover Image

Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE ADTM study

Aims: Patients treated with anticoagulants may experience serious bleeding or require urgent surgery or intervention, and may benefit from rapid anticoagulant reversal. This exploratory analysis assessed healthcare resource utilization (HCRU) in patients treated with idarucizumab, a specific reversa...

Full description

Saved in:
Bibliographic Details
Main Authors: Pollack, Charles V. (Author) , Steiner, Thorsten (Author)
Format: Article (Journal)
Language:English
Published: 17 Jan 2017
In: Journal of medical economics
Year: 2016, Volume: 20, Issue: 5, Pages: 435-442
ISSN:1941-837X
DOI:10.1080/13696998.2016.1273229
Online Access:Verlag, Volltext: http://dx.doi.org/10.1080/13696998.2016.1273229
Verlag, Volltext: https://doi.org/10.1080/13696998.2016.1273229
Get full text
Author Notes:Charles V. Pollack Jr, Richard Bernstein, Robert Dubiel, Paul Reilly, Fredrik Gruenenfelder, Menno V. Huisman, Chak-Wah Kam, Eva Kleine, Jerrold H. Levy, Frank W. Sellke, Thorsten Steiner, Anastasia Ustyugova, Jeffrey I. Weitz

MARC

LEADER 00000caa a2200000 c 4500
001 1576295052
003 DE-627
005 20220814161745.0
007 cr uuu---uuuuu
008 180612r20172016xx |||||o 00| ||eng c
024 7 |a 10.1080/13696998.2016.1273229  |2 doi 
035 |a (DE-627)1576295052 
035 |a (DE-576)506295052 
035 |a (DE-599)BSZ506295052 
035 |a (OCoLC)1341011537 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pollack, Charles V.  |e VerfasserIn  |0 (DE-588)140620974  |0 (DE-627)703735160  |0 (DE-576)319144860  |4 aut 
245 1 0 |a Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions  |b interim results from the RE-VERSE ADTM study  |c Charles V. Pollack Jr, Richard Bernstein, Robert Dubiel, Paul Reilly, Fredrik Gruenenfelder, Menno V. Huisman, Chak-Wah Kam, Eva Kleine, Jerrold H. Levy, Frank W. Sellke, Thorsten Steiner, Anastasia Ustyugova, Jeffrey I. Weitz 
246 3 0 |a ad tm 
264 1 |c 17 Jan 2017 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Accepted author version posted online: 16 Dec 2016 
500 |a Im Titel ist "TM" hochgestellt 
500 |a Gesehen am 12.06.2018 
520 |a Aims: Patients treated with anticoagulants may experience serious bleeding or require urgent surgery or intervention, and may benefit from rapid anticoagulant reversal. This exploratory analysis assessed healthcare resource utilization (HCRU) in patients treated with idarucizumab, a specific reversal agent for dabigatran etexilate.Materials and methods: RE-VERSE AD TM (NCT02104947), a prospective, multi-center open-label study, is evaluating idarucizumab for dabigatran reversal in patients with serious bleeding (Group A) or undergoing emergency surgery/procedures (Group B). HCRU outcome measures evaluated in the first 90 patients enrolled were use of blood products and pro-hemostatic agents, length of stay (LOS) in hospital, and LOS in intensive care unit (ICU).Results: Blood products or pro-hemostatic agents were given to 63% (32/51) of patients in Group A and 23% (9/39) of patients in Group B on the day of/day after surgery. An overnight hospital stay was reported for 82% (42/51) of patients in Group A with median LOS = 7 (range = 1-71) bed-days. For Group B, 92% (36/39) had an overnight hospital stay with a median LOS = 9 (range = 1-92) bed-days. In Group A, 17 patients were admitted to the ICU for at least 1 day with median LOS = 4 (range = 1-44) days; in Group B the number was 15 with median LOS = 2 (range = 1-92) days. Limitations: The lack of a control group and the small patient numbers limit the strength of the conclusions. Conclusions: The use of idarucizumab may simplify emergency management of dabigatran-treated patients with life-threatening bleeds and reduce perioperative complications in patients undergoing emergency surgery. 
534 |c 2016 
650 4 |a anticoagulation reversal 
650 4 |a dabigatran etexilate 
650 4 |a Healthcare resource utilization 
650 4 |a idarucizumab 
650 4 |a reversal agent 
700 1 |a Steiner, Thorsten  |d 1961-  |e VerfasserIn  |0 (DE-588)118107623  |0 (DE-627)079247407  |0 (DE-576)291718779  |4 aut 
773 0 8 |i Enthalten in  |t Journal of medical economics  |d Abingdon : Taylor & Francis Group, 1998  |g 20(2017), 5, Seite 435-442  |w (DE-627)392234564  |w (DE-600)2156786-4  |w (DE-576)35062416X  |x 1941-837X  |7 nnas  |a Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions interim results from the RE-VERSE ADTM study 
773 1 8 |g volume:20  |g year:2017  |g number:5  |g pages:435-442  |g extent:8  |a Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions interim results from the RE-VERSE ADTM study 
856 4 0 |u http://dx.doi.org/10.1080/13696998.2016.1273229  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://doi.org/10.1080/13696998.2016.1273229  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180612 
993 |a Article 
994 |a 2017 
998 |g 118107623  |a Steiner, Thorsten  |m 118107623:Steiner, Thorsten  |d 910000  |d 911100  |e 910000PS118107623  |e 911100PS118107623  |k 0/910000/  |k 1/910000/911100/  |p 11 
999 |a KXP-PPN1576295052  |e 3012551948 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"doi":["10.1080/13696998.2016.1273229"],"eki":["1576295052"]},"physDesc":[{"extent":"8 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions","title":"Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions","subtitle":"interim results from the RE-VERSE ADTM study"}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"17 Jan 2017"}],"relHost":[{"recId":"392234564","title":[{"title_sort":"Journal of medical economics","title":"Journal of medical economics","subtitle":"JME"}],"id":{"eki":["392234564"],"issn":["1941-837X"],"zdb":["2156786-4"]},"origin":[{"publisherPlace":"Abingdon ; Richmond ; New York, NY","dateIssuedKey":"1998","dateIssuedDisp":"1998-","publisher":"Taylor & Francis Group ; PJB Publ. ; Informa Healthcare"}],"language":["eng"],"part":{"volume":"20","year":"2017","issue":"5","pages":"435-442","extent":"8","text":"20(2017), 5, Seite 435-442"},"note":["Gesehen am 03.06.2022"],"pubHistory":["1.1998 -"],"disp":"Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions interim results from the RE-VERSE ADTM studyJournal of medical economics","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"JME"}]}],"name":{"displayForm":["Charles V. Pollack Jr, Richard Bernstein, Robert Dubiel, Paul Reilly, Fredrik Gruenenfelder, Menno V. Huisman, Chak-Wah Kam, Eva Kleine, Jerrold H. Levy, Frank W. Sellke, Thorsten Steiner, Anastasia Ustyugova, Jeffrey I. Weitz"]},"language":["eng"],"note":["Accepted author version posted online: 16 Dec 2016","Im Titel ist \"TM\" hochgestellt","Gesehen am 12.06.2018"],"recId":"1576295052","person":[{"given":"Charles V.","display":"Pollack, Charles V.","family":"Pollack","role":"aut"},{"display":"Steiner, Thorsten","given":"Thorsten","role":"aut","family":"Steiner"}]} 
SRT |a POLLACKCHAHEALTHCARE1720 

Similar Items